Vonoprazan treatment results in fewer episodes of nighttime heartburn and reduces symptom severity in patients with ...
Investor's Business Daily on MSN
Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk
Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback